Cargando…

Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study

Background: Pembrolizumab is currently the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). However, the association between immune-related adverse events (irAEs) and peripheral blood cell counts remains unclear. We aimed at identifying peripheral blood cell counts t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Egami, Saeka, Kawazoe, Hitoshi, Hashimoto, Hironobu, Uozumi, Ryuji, Arami, Toko, Sakiyama, Naomi, Ohe, Yuichiro, Nakada, Hideo, Aomori, Tohru, Ikemura, Shinnosuke, Fukunaga, Koichi, Yamaguchi, Masakazu, Nakamura, Tomonori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974524/ https://www.ncbi.nlm.nih.gov/pubmed/33754009 http://dx.doi.org/10.7150/jca.53242

Ejemplares similares

Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study
por: Egami, Saeka, et al.
Publicado: (2021)

Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study
por: Ogiwara, Toshiki, et al.
Publicado: (2021)

Lorlatinib‐induced visual and auditory hallucinations: A case report
por: Hakamata, Jun, et al.
Publicado: (2021)

Prognostic Model of Baseline Medications plus Neutrophil-to-lymphocyte Ratio in Patients with Advanced Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitor plus Platinum Doublet: A Multicenter Retrospective Study
por: Nasu, Izumi, et al.
Publicado: (2023)

Successful Steroid Treatment of Pembrolizumab-induced Agranulocytosis That Developed after Splenectomy in a Patient with Non-small-cell Lung Cancer
por: Okuzumi, Shinichi, et al.
Publicado: (2022)

Chromatography columns packed with thermoresponsive-cationic-polymer-modified beads for therapeutic drug monitoring
por: Nagase, Kenichi, et al.
Publicado: (2022)

Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study
por: Ishikawa, Emi, et al.
Publicado: (2023)

Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study
por: Kawazoe, Hitoshi, et al.
Publicado: (2018)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
por: Takumida, Hiroshi, et al.
Publicado: (2021)

Proton pump inhibitors affect capecitabine efficacy in patients with stage II–III colorectal cancer: a multicenter retrospective study
por: Kitazume, Yoshiko, et al.
Publicado: (2022)

Pembrolizumab‐related pancreatitis with elevation of pancreatic tumour markers
por: Kakuwa, Tamaki, et al.
Publicado: (2020)

Effect of Ethanol in Paclitaxel Injections on the Ethanol Concentration in Exhaled Breath
por: Aomori, Tohru, et al.
Publicado: (2012)

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2013)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2012)

Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series
por: Inaba‐Higashiyama, Ryoko, et al.
Publicado: (2020)

Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis
por: Yamazaki, Tomoko, et al.
Publicado: (2022)

Sex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A5*3/*3
por: Ito, Ayano, et al.
Publicado: (2017)

Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B)
por: Ozeki, Rie, et al.
Publicado: (2022)

Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab
por: Kadota, Naoki, et al.
Publicado: (2021)

A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy
por: Shinozaki, Taro, et al.
Publicado: (2018)

Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials
por: Yamamoto, Senri, et al.
Publicado: (2021)

Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis
por: Yamamoto, Senri, et al.
Publicado: (2022)

The Development of a Skin Cancer Classification System for Pigmented Skin Lesions Using Deep Learning
por: Jinnai, Shunichi, et al.
Publicado: (2020)

Systemic Psoriasiform Dermatitis Appeared after the Administration of Pembrolizumab
por: Suzuki, Manabu, et al.
Publicado: (2019)

Two Cases of Pembrolizumab-Induced Secondary Adrenal Insufficiency
por: Kanzaki, Akinori, et al.
Publicado: (2021)

Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study
por: Tashiro, Ryota, et al.
Publicado: (2022)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

A Querying Method over RDF-ized Health Level Seven v2.5 Messages Using Life Science Knowledge Resources
por: Kawazoe, Yoshimasa, et al.
Publicado: (2016)

Machine learning-based prediction of in-hospital mortality using admission laboratory data: A retrospective, single-site study using electronic health record data
por: Seki, Tomohisa, et al.
Publicado: (2021)

Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study
por: Tashiro, Ryota, et al.
Publicado: (2023)

Characteristics of pulmonary cryptococcosis in patients with rheumatoid arthritis
por: Hosoda, Chiaki, et al.
Publicado: (2021)

Choking injuries: Associated factors and error-producing conditions among acute hospital patients in Japan
por: Akiyama, Naomi, et al.
Publicado: (2022)

Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Ito, Masami, et al.
Publicado: (2012)

A user-friendly tool to transform large scale administrative data into wide table format using a mapreduce program with a pig latin based script
por: Horiguchi, Hiromasa, et al.
Publicado: (2012)

Pembrolizumab for all
por: Kim, Myung S., et al.
Publicado: (2022)

Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
por: Fukuta, Kyotaro, et al.
Publicado: (2021)

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
por: Oishi, Hideo, et al.
Publicado: (2020)

Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer
por: Ueki, Yuriko, et al.
Publicado: (2020)

Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy
por: Kawahara, Takashi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3jn4dtao74gjqmmge3r02b0cgs